You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Diagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild and moderate Alzheimer's disease

    SBC: APTUS BIOSCIENCES LLC            Topic: NIA

    Diagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild andmoderate Alzheimer’s disease Aptus Biosciences, LLCBharat Gawande SummaryToday, 6.2 million Americans are living with Alzheimer’s disease (AD), resulting in $355 billion in annual medical care costs. As the US population over age 65 grows, the number of Americans living with AD is expected to increase to ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Process development for manufacturing eCD4-Ig

    SBC: EMMUNE INC            Topic: NIAID

    ABSTRACTeCD4-Ig is an antibody-like therapeutic for HIV that was constructed by fusing CD4 domains 1 and 2, and an HIV coreceptor-mimetic sulfopeptide, to the N- and C-termini of the constant Fc region of an antibody. eCD4-Ig will join an emerging class of long-acting therapeutics for treating and preventing HIV infection. As a consequence of being built from parts of HIV’s receptors, eCD4-Ig ne ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Engineering next generation probiotics for delivery of therapeutics

    SBC: Medosome Biotec, LLC            Topic: NCATS

    PROJECT SUMMARY / ABSTRACT Peptide and protein drugs (PPDs) are potent therapeutics to treat a broad spectrum of diseases. Parenteral administration is limited due to their poor bioavailability and stability. Oral delivery of PPDs faces additional obstacles in the gastrointestinal tract. We have developed an innovative, probiotics-based platform technology for the oral delivery of therapeutic PPDs ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A multi-sensor catheter for diagnosing obstructive sleep apnea

    SBC: BOLD TYPE LLC            Topic: NHLBI

    Project Summary Few medical disorders have a larger public health impact than Obstructive Sleep Apnea (OSA). OSA affects more than 20 million people in the US alone, and when untreated, it is associated with significant comorbidities and mortality. Current diagnostic tests for OSA, however, are expensive, inconvenient, and largely ineffective. Overnight in-facility sleep studies, also known as pol ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. A device to treat high-tone pelvic floor dysfunction in women

    SBC: BOLD TYPE LLC            Topic: NICHD

    Abstract Bold Type is developing the “SmartWand”, an interactive, connected pelvic floor system (device and mobile app) to guide patients through pelvic floor physical therapy (PT) in the privacy of their home. PT is a highly effective and first-line treatment for high tone pelvic floor dysfunction (HTPFD), a major contributor to chronic pelvic pain (CPP), affecting up to 15% of women in the U ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced CLAD PERG system with minimal patient preparation for clinical settings (Phase II)

    SBC: JORVEC CORP.            Topic: NEI

    Abstract: Glaucoma is one of a number of optic nerve diseases which lead to retinal ganglion cells (RGC) degeneration, ultimately manifesting in a functional loss of vision if left untreated. There exist a number of therapeutic approaches to treat these conditions, but there are currently no clinical methods to detect the onset of RGC dysfunction. The Pattern Electroretinogram (PERG) is the only e ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. High-Throughput Screening for the Discovery of Protein-Binding Fragments

    SBC: DELUGE BIOTECHNOLOGIES INC            Topic: 400

    Project Summary Fragment based drug discovery programs begin with the identification of low molecular compounds that bind weakly to the protein of interest (POI). POI-binding fragments are then elaborated and/or linked together to provide lead compounds. Current methods for screening fragment libraries have low throughput and many require large amounts of the POI, often in isotopically labeled for ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Interactive Fiction story to teach college readiness executive functioning skills to college-bound students with ASD and ADHD

    SBC: OBJECTIVE ED, INC.            Topic: 500

    Project Summary: (30 lines) CTS – College Transition Stories This Phase I SBIR project will determine the feasibility of using an Accessible Interactive Fiction (AIF) story to help students with autism spectrum disorder (ASD), 16 to 21 years old, who are college-bound (CBASD), to improve their ability to succeed in a college environment. Research has shown that practicing college readiness skill ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Deep-CDS: Deep Learning Semantic Data Lake for Clinical Decision Support

    SBC: INFOTECH SOFT, INC.            Topic: 300

    More than 5 million patients are admitted annually to United States ICUs with average mortality rate reported ranging from 8-19%, or about 500,000 deaths annually. Sepsis is the leading cause of in-hospital mortality, where one in three inpatient deaths are due to sepsis. Incidence of sepsis has been increasing with 1.7 million sepsis cases and 270,000 deaths per year. Early identification of dete ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Integrin-Targeted Novel Oral Therapeutics for Lupus Nephritis

    SBC: 149 BIO LLC            Topic: NIAID

    Project SummaryLupus nephritis (LN) remains the strongest predictor of morbidity and mortality for people with Systemic Lupus Erythematosus (SLE), an autoimmune disease disproportionately affecting women and minorities. The current standard of care for LN, glucocorticoids and immunosuppressive agents, has many side effects and long-term toxicity. Therefore, there is an urgent and unmet need for ta ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government